Prostate-specific antigen (PSA) is a widely available and analytically robust biomarker, but its role in prostate cancer (PCa) screening remains controversial due to concerns regarding limited specificity, overdiagnosis of indolent tumors, and the downstream risk of overtreatment. The gene discussed is KLK3; the disease is Familial prostate cancer.